Trading Report: The Trillium Asset Management LLC cuts its investment of stake in Omnicell Inc. (OMCL)

The Trillium Asset Management LLC cuts its investment of stake in Omnicell Inc. (OMCL)

Trillium Asset Management LLC reduced its position in Omnicell Inc. (NASDAQ:OMCL) by 1.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,885 shares of the company’s stock after selling 633 shares during the period. Trillium Asset Management LLC’s holdings in Omnicell were worth $1,468,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in OMCL. Capstone Asset Management Co. increased its stake in Omnicell by 7.9% in the second quarter. Capstone Asset Management Co. now owns 13,693 shares of the company’s stock worth $469,000 after buying an additional 1,000 shares during the last quarter. Fisher Asset Management LLC increased its stake in Omnicell by 1.0% in the second quarter. Fisher Asset Management LLC now owns 536,152 shares of the company’s stock worth $19,452,000 after buying an additional 5,152 shares during the last quarter. DNB Asset Management AS increased its stake in Omnicell by 858.6% in the second quarter. DNB Asset Management AS now owns 133,249 shares of the company’s stock worth $4,561,000 after buying an additional 119,348 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Omnicell by 105.4% in the second quarter. BNP Paribas Arbitrage SA now owns 11,522 shares of the company’s stock worth $394,000 after buying an additional 5,913 shares during the last quarter. Finally, Royal Bank of Canada increased its stake in Omnicell by 0.8% in the first quarter. Royal Bank of Canada now owns 685,223 shares of the company’s stock worth $19,097,000 after buying an additional 5,387 shares during the last quarter. Institutional investors own 95.26% of the company’s stock.

Omnicell Inc. (NASDAQ:OMCL) traded down 0.30% during trading on Friday, hitting $36.79. The stock had a trading volume of 165,963 shares. The stock has a 50 day moving average price of $37.88 and a 200-day moving average price of $33.96. Omnicell Inc. has a 12 month low of $25.06 and a 12 month high of $40.50. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of 93.38 and a beta of 0.58.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.06. The business earned $175.60 million during the quarter, compared to analysts’ expectations of $170.89 million. Omnicell had a return on equity of 10.41% and a net margin of 2.36%. The firm’s revenue for the quarter was up 55.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.28 EPS. On average, equities analysts predict that Omnicell Inc. will post $1.58 EPS for the current year.

Several brokerages have weighed in on OMCL. Sidoti downgraded Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price objective for the company. in a research report on Thursday, September 8th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $46.00 price objective on shares of Omnicell in a research report on Tuesday, September 13th. Zacks Investment Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. Finally, FBR & Co boosted their price objective on Omnicell from $40.00 to $41.00 and gave the company an “outperform” rating in a research report on Friday, July 29th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $38.13.

In other news, Chairman Randall A. Lipps sold 37,425 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $37.37, for a total value of $1,398,572.25. Following the completion of the sale, the chairman now directly owns 192,325 shares of the company’s stock, valued at approximately $7,187,185.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gary S. Petersmeyer sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, September 12th. The shares were sold at an average price of $37.98, for a total value of $75,960.00. Following the completion of the sale, the director now directly owns 17,987 shares of the company’s stock, valued at $683,146.26. The disclosure for this sale can be found here. Company insiders own 3.75% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

Related posts

Leave a Comment